Endometrial Cancers in
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
2019
2019
Historique:
accepted:
24
07
2019
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
12
9
2020
Statut:
epublish
Résumé
Endometrial cancer (EC) is not considered a component of the hereditary breast and ovarian cancer syndrome but can arise in patients with germline Of 769 patients with EC who underwent germline panel testing, 10 pathogenic g Of the 13 patients included who had EC, eight harbored pathogenic g A subset of g
Identifiants
pubmed: 32914019
doi: 10.1200/PO.19.00103
pii: 1900103
pmc: PMC7446423
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009512
Pays : United States
Informations de copyright
© 2019 by American Society of Clinical Oncology.
Déclaration de conflit d'intérêts
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Karen A. CadooResearch Funding: AstraZeneca (Inst), Syndax (Inst) Travel, Accommodations, Expenses: AstraZenecaNadeem R. Abu-RustumHonoraria: Prime Oncology Research Funding: Stryker/Novadaq (Inst), Olympus (Inst), GRAIL (Inst) Travel, Accommodations, Expenses: Prime OncologyNadeem RiazHonoraria: PeerView Speakers' Bureau: Illumina Research Funding: Bristol-Myers Squibb, Pfizer Travel, Accommodations, Expenses: Varian Medical SystemsMark E. RobsonHonoraria: AstraZeneca Consulting or Advisory Role: McKesson, AstraZeneca Research Funding: AstraZeneca (Inst), Myriad Genetics (Inst), InVitae (Inst), AbbVie (Inst), Tesaro (Inst), Medivation (Inst) Travel, Accommodations, Expenses: AstraZeneca, Pfizer Other Relationship: Research to Practice, Clinical Care Options, Physician Education ResourceRobert A. SoslowSpeakers' Bureau: Ebix/Oakstone Patents, Royalties, Other Intellectual Property: Methods for diagnosis and treatment of endometrial cancer. Assignee: 2015 The Regents of the University of California 8/18/2015 (Inst); Application: Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function (Inst); Royalties from published books: Cambridge University Press and Springer PublishingJorge S. Reis-FilhoConsulting or Advisory Role: Roche, Invicro, Ventana Medical Systems, Volition RX, Paige.AI, Goldman Sachs, NovartisBritta WeigeltConsulting or Advisory Role: Roche (I), Invicro (I), Ventana Medical Systems (I), Volition RX (I), Paige.AI (I), Goldman Sachs (I), Novartis (I) No other potential conflicts of interest were reported.
Références
Mod Pathol. 2016 Aug;29(8):893-903
pubmed: 27150160
Oncogene. 2006 Sep 25;25(43):5864-74
pubmed: 16998501
Nat Commun. 2017 Aug 22;8(1):319
pubmed: 28831036
Clin Cancer Res. 2014 Feb 1;20(3):764-75
pubmed: 24240112
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Nucleic Acids Res. 1997 Jun 15;25(12):2532-4
pubmed: 9171110
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Clin Cancer Res. 2017 Jun 1;23(11):2617-2629
pubmed: 28572256
J Natl Cancer Inst. 2019 Jul 1;111(7):737-741
pubmed: 30649385
N Engl J Med. 2017 Oct 12;377(15):1409-1412
pubmed: 29020592
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243
pubmed: 27791010
Cancer Discov. 2018 Feb;8(2):174-183
pubmed: 29247016
Gynecol Oncol. 2019 Jan;152(1):11-19
pubmed: 30415991
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Oncologist. 2018 Jun;23(6):650-653
pubmed: 29472312
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Nat Biotechnol. 2012 May;30(5):413-21
pubmed: 22544022
Cancer Res. 2012 Nov 1;72(21):5454-62
pubmed: 22933060
Gynecol Oncol. 2015 Jun;137(3):581-8
pubmed: 25805398
Nat Commun. 2014 Sep 19;5:5006
pubmed: 25233892
Mod Pathol. 2016 Mar;29(3):302-14
pubmed: 26743474
Cancer Treat Rev. 2019 Feb;73:1-9
pubmed: 30543930
JAMA. 2017 Sep 5;318(9):825-835
pubmed: 28873162
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:37-50
pubmed: 30306580
JCO Precis Oncol. 2017;2017:
pubmed: 30211344
Cell. 2018 Apr 5;173(2):355-370.e14
pubmed: 29625052
JAMA Oncol. 2016 Nov 1;2(11):1434-1440
pubmed: 27367496
Am J Surg Pathol. 2007 May;31(5):744-51
pubmed: 17460459
Nat Rev Clin Oncol. 2016 Jan;13(1):41-54
pubmed: 26483301
Gynecol Oncol. 2013 Jul;130(1):127-31
pubmed: 23562522
Nat Commun. 2017 Oct 11;8(1):857
pubmed: 29021619
Nat Commun. 2018 May 8;9(1):1816
pubmed: 29739933
Mod Pathol. 2012 Apr;25(4):625-36
pubmed: 22193042
Science. 2003 Oct 24;302(5645):643-6
pubmed: 14576434
Bioinformatics. 2014 Apr 1;30(7):1015-6
pubmed: 24371154
Nat Genet. 2019 May;51(5):912-919
pubmed: 30988514
J Pathol. 2015 Oct;237(2):179-89
pubmed: 26095796
Cancer. 2013 Jan 15;119(2):332-8
pubmed: 22811390
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Genome Biol. 2016 Feb 22;17:31
pubmed: 26899170
Int J Cancer. 2017 Mar 15;140(6):1396-1404
pubmed: 27905110
Histopathology. 2017 Feb;70(3):359-366
pubmed: 27656868
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110